PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Nasal Obstruction

Drugs in development · updated 30 October 2026

Nasal Obstruction: drugs in development

As of 30 October 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for nasal Obstruction. 2 are experimental, that is not yet approved in the United States.

4Active trials
2Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
DIPYRONEMetamizoleIII1NCT07626437
ApomivirII1NCT01677689

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CaffeineCafcit®, Gencebok®III1NCT07626437
CephalexinKeftab®, Keflet®III1NCT04194216
ChlorpheniramineEfidac 24 Chlorpheniramine Maleate®, Teldrin®III1NCT07626437
ClindamycinXaciato®, Clindamycin Phosphate In 0.9% Sodium Chloride®III1NCT04194216
BudesonideTarpeyo®, Eohilia®II1NCT06830109
Oxymetazoline Nasal SprayUpneeq®, Rhofade®II1NCT06830109

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D015508 “Nasal Obstruction”.

ItalianoFrançaisDeutsch